30 closest matches · ranked by relevance
Colon Adenocarcinoma · High-Frequency Microsatellite Instability · Metastatic Malignant Solid Neoplasm
Primary: Percentage of Circulating DNA Clearance — 0 percentage of DNA cleared
Colorectal Adenocarcinoma · Metastatic Microsatellite Stable Colorectal Carcinoma · Refractory Colorectal Carcinoma
Primary: Overall Response Rate (ORR) — 2; 16 Participants
MSS · RAS-mutant Colorectal Cancer
Primary: Phase 1b: Number of Participants With Dose-Limiting Toxicities (DLT) — 1; 2 Participants
Refractory Metastatic Colorectal Cancer
Primary: Immune-Related Overall Response Rate (irORR) — 0 percentage of participants
Colorectal Carcinoma
Primary: Objective Response Rate (ORR) - Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) Assessed by Central Imaging Vendor — 32.8; 34.9 Percentage of participants
Colorectal Cancer
Primary: Durable Clinical Benefit — 3; 32 Participants
Metastatic Colorectal Cancer · MSS
Primary: Feasibility Rate of a Combined Therapy — 18 Participants
Malignant Neoplasms of Digestive Organs · Colorectal Cancer · Colon Cancer
Primary: Immune-related Best Overall Response Rate. — 1 Participants
Microsatellite Stable (MSS) Colorectal Adenocarcinomas · Colorectal Adenocarcinoma
Primary: Objective Response Rate (ORR) — 0; 1; 2 Participants
High Tumor Mutation Burden · High TMB (Tumor Mutation Burden) · MSS (Microsatellite Stable)
Primary: Objective Response Rate (ORR) in Patients With MSI (Microsatellite Unstable)-Negative Solid Tumor Malignancies With a Mutator Phenotype — 5 Participants
Colorectal Neoplasms · Microsatellite Instability
Primary: Overall Response Rate (ORR) — 0 % of participants
MSI Positive Colorectal Cancer · MSI Negative Colorectal Cancer · MSI Positive Non-Colorectal Cancers
Primary: Immune-related Progression Free Survival (irPFS) at 20 Weeks in MSI Positive and Negative Colorectal Adenocarcinoma Participants Using Immune Related Response Criteria…
Colorectal Cancer Metastatic
Primary: Overall Objective Response Rate (ORR) of Dual Immune Checkpoint Blockade by RECIST 1.1 — 9.52 percentage of participants
Metastatic Colorectal Cancer
Primary: Objective Response Rates (RECIST 1.1) — 42.4 Percentage of participants
Colon Cancer
Primary: Overall Response Rate — 32 percentage of participants
Colorectal Cancer
Primary: Overall Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 Assessed by Investigator — 7.1 percentage (%) of participants — p=0.2721
Unresectable or Metastatic Microsatellite Stable (MSS) Solid Tumor · Microsatellite Stable (MSS) Colon Cancer
Primary: Number of Participants Experiencing a Dose Limiting Toxicity — 0 Participants
Locally Advanced Malignant Solid Neoplasm
Primary: Pathological Complete Response (pCR). — 67 Percentage
Colorectal Carcinoma
Primary: Progression-Free Survival (PFS) Per RECIST1.1 As Assessed by Central Imaging Vendor — 16.5; 8.2 Months — p=0.0001
Colorectal Cancer Metastatic
Primary: Primary - Progression-free Survival (PFS) — 9.2; 9.2 Months of progression-free survival
Colorectal Cancer · Colorectal Carcinoma · Colorectal Adenocarcinoma
Primary: Number of Participants With Grade 1-5 Adverse Events — 4; 12; 4; 13 Participants
Colorectal Cancer
Primary: RXC004 Monotherapy (Arm A): Disease Control Rate (DCR) Using Each Patient's Best Overall Response (BOR) According to Response Evaluation Criteria in Solid Tumours…
Gastric Adenocarcinoma · Gastroesophageal Junction Adenocarcinoma
Primary: RR — 15 Participants
Advanced/Metastatic Solid Malignancies
Primary: Overall Response Rate (Confirmed) — 1; 1 Participants
Solid Tumor, Adult
Primary: Immune-related Objective Response Rate — 9 Participants
Solid Tumors
Primary: Number of Participants With Dose Limiting Toxicity (DLT) — 0; 0; 1 Participants
Colorectal Cancer
Primary: Major Pathological Response (MPR) Rate — 89.7 Percentage of Participants
Solid Tumors
Primary: Dose-escalation: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs — 3; 3; 4; 3 Participants
Pancreatic Cancer Non-resectable · Pancreatic Cancer Metastatic
Primary: Disease Control Rate (DCR) at 4 Months Using RECIST 1.1 — 2 Participants
Colorectal Cancer
Primary: Tumour Response — 0; 0 Percentage of Participants